Sarcopenia predicts immune-related adverse events due to anti-PD-1/PD-L1 therapy in patients with advanced lung cancer
irAEs are prevalent side effects of PD-1/PD-L1 inhibitor therapy for patients with cancer. By diagnosing and treating sarcopenia early, it is possible to lower the potential risk of irAEs in patients with advanced cancer. Furthermore, sarcopenia can be utilized as a predictor of irAEs.
Authors
- Kaiya Men
- Jiaxin Yang (ORCID: https://orcid.org/0000-0002-1276-1136)
- Xu Zhao (ORCID: https://orcid.org/0000-0002-5053-5551)
- Dinglong Xue
- Shuai Zhang (ORCID: https://orcid.org/0000-0003-0272-0856)
- Ning Li
- Lijun Li (ORCID: https://orcid.org/0000-0003-0443-0596)
- Hao Jiang (ORCID: https://orcid.org/0000-0002-1182-8132)
Institutions
- Harbin Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-09-23
- DOI
- https://doi.org/10.3389/fonc.2024.1450020
- Citations
- 7
- Primary Topic
- Nutrition and Health in Aging
- Type
- article
- Field-Weighted Citation Impact
- 2.29